Related references
Note: Only part of the references are listed.Post-transcriptional regulations of cancer stem cell homeostasis
Nabila Berabez et al.
CURRENT OPINION IN ONCOLOGY (2019)
Characterization of SGN-CD123A, APotent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia
Fu Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates
Donglu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia
Cathy C. Zhang et al.
NEOPLASIA (2018)
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells
Themis Alissafi et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Identification of the tumour transition states occurring during EMT
Ievgenia Pastushenko et al.
NATURE (2018)
Cancer stem cell pipeline flounders
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2018)
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Nirnoy Dan et al.
PHARMACEUTICALS (2018)
5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma
Samuel A. Kerk et al.
CLINICAL CANCER RESEARCH (2017)
Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia
Owen J. McGinn et al.
HAEMATOLOGICA (2017)
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
Geoffrey I. Shapiro et al.
INVESTIGATIONAL NEW DRUGS (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells
Fabrizio Marcucci et al.
MOLECULAR CANCER (2017)
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4
Jay Harper et al.
MOLECULAR CANCER THERAPEUTICS (2017)
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Marc Damelin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia
Owen J. McGinn et al.
HAEMATOLOGICA (2017)
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
Mark A. Socinski et al.
CLINICAL LUNG CANCER (2017)
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Boris Shor et al.
CLINICAL CANCER RESEARCH (2016)
Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma
Arokia Priyanka Vaz et al.
ONCOTARGET (2016)
Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific
Benson Gikanga et al.
BIOCONJUGATE CHEMISTRY (2016)
In silico modeling for tumor growth visualization
Fleur Jeanquartier et al.
BMC SYSTEMS BIOLOGY (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
Manisha H. Shah et al.
INVESTIGATIONAL NEW DRUGS (2016)
LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Xing Gong et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Epithelial-mesenchymal transition: a new target in anticancer drug discovery
Fabrizio Marcucci et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal
Fabrizio Marcucci et al.
FRONTIERS IN ONCOLOGY (2016)
Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Wan-Ching Yen et al.
CLINICAL CANCER RESEARCH (2015)
Anti-EFNA4 Calichearnicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
Marc Damelin et al.
CLINICAL CANCER RESEARCH (2015)
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Naoko Takebe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
Marc Damelin et al.
PHARMACEUTICAL RESEARCH (2015)
Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer
Melissa R. Junttila et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
LGR5, a relevant marker of cancer stem cells, indicates a poor prognosis in colorectal cancer patients: A meta-analysis
Ye Han et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2015)
Epigenetic Targeting of Ovarian Cancer Stem Cells
Yinu Wang et al.
CANCER RESEARCH (2014)
LGR5 positivity defines stem-like cells in colorectal cancer
Daniela Hirsch et al.
CARCINOGENESIS (2014)
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads
Fabrizio Marcucci et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Tackling the cancer stem cells - what challenges do they pose?
Diwakar R. Pattabiraman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Therapeutic targeting of EPH receptors and their ligands
Andrew W. Boyd et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer
Hong-Qing Xi et al.
ONCOLOGY REPORTS (2014)
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
J. Diessner et al.
CELL DEATH & DISEASE (2014)
Pathology and Diagnosis of Neuroendocrine Tumors: Lung Neuroendocrine
William D. Travis
THORACIC SURGERY CLINICS (2014)
Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
Suling Liu et al.
STEM CELL REPORTS (2014)
HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
Suthinee Ithimakin et al.
CANCER RESEARCH (2013)
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets
Naomi Pode-Shakked et al.
EMBO MOLECULAR MEDICINE (2013)
Human monoclonal antibodies in cancer therapy: a review of recent developments
Lin Xin et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2013)
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Christina M. Annunziata et al.
INVESTIGATIONAL NEW DRUGS (2013)
Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Puja Sapra et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells
Fabrizio Marcucci et al.
MABS (2013)
The epigenetics of epithelial-mesenchymal plasticity in cancer
Wai Leong Tam et al.
NATURE MEDICINE (2013)
Understanding cancer stem cell heterogeneity and plasticity
Dean G. Tang
CELL RESEARCH (2012)
Improving drug penetration to curb tumor drug resistance
Fabrizio Marcucci et al.
DRUG DISCOVERY TODAY (2012)
LGR5 Interacts and Cointernalizes with Wnt Receptors To Modulate Wnt/β-Catenin Signaling
Kendra S. Carmon et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The developing cancer stem-cell model: clinical challenges and opportunities
Louis Vermeulen et al.
LANCET ONCOLOGY (2012)
Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes
Jeffrey J. Wallin et al.
PLOS ONE (2012)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Marc Damelin et al.
CANCER RESEARCH (2011)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis
Gavin Chapman et al.
HUMAN MOLECULAR GENETICS (2011)
Breast cancer stem cells, cytokine networks, and the tumor microenvironment
Hasan Korkaya et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Laurent Ducry et al.
BIOCONJUGATE CHEMISTRY (2010)
EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
Jeong-Won Lee et al.
CLINICAL CANCER RESEARCH (2010)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Jagath R. Junutula et al.
CLINICAL CANCER RESEARCH (2010)
Antibody-drug conjugates: targeted drug delivery for cancer
Stephen C. Alley et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
Andrew G. Polson et al.
CANCER RESEARCH (2009)
Crypt stem cells as the cells-of-origin of intestinal cancer
Nick Barker et al.
NATURE (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Efficient tumour formation by single human melanoma cells
Elsa Quintana et al.
NATURE (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
Philip A. Gregory et al.
NATURE CELL BIOLOGY (2008)
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers
Nancy Dumont et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells
Helen L. Spencer et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors
Muthusamy Kunnimalaiyaan et al.
ONCOLOGIST (2007)
Emerging roles of pseudokinases
Jerome Boudeau et al.
TRENDS IN CELL BIOLOGY (2006)
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)
YH Guan et al.
BLOOD (2003)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Share Paper
